Allain H., et al, “Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg,” Human Psychopharmacology. 2003;18(5):369-374.
Ancoli-Israel S., et al, “A novel non-benzodizepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects.” Primary Care. 1999;1:114-120.
Buscemi N., et al, “Manifestations and management of chronic insomnia in adults. Evidence report/technology assessment No. 125. Rockville, MD: Prepared by the University of Alberta Evidence-based Practice Center; 2005.
Buscemi N, Vandermeer B, Friesen C, et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-1350. doi:10.1007/s11606-007-0251-z.
Colten H.R., Altevogt, B.M. (editors), “Sleep disorders and sleep deprivation: an unmet public health problem,” Institute of Medicine, National Academy of Sciences (April 2006), www.national-academies.org.
Dorsey C.M., et al, “Effect of Zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: A 4-week, randomized, multicenter, doubleblind, placebo-controlled study. Clin. Ther. 2004;26 (10):1578-1586.
Drugs for Insomnia. Treat Guidel Med Lett. 2012;10(119):57-60.
Dundar Y. et al, “Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: A systematic review and meta-analysis.” Human Psychopharmacology. 2004;19(5):305-322.
Edinger JD, Wholgemuth WK, Radtke RA, Marsh GR, Quillian RE. Cognitive Behavioral Therapy for Treatment of Chronic Primary Insomnia: A Randomized Controlled Trial. JAMA. 2001;285:1856-1864. doi:10.1001/jama.285.14.1856.
Elie R., et al, “Sleep latency is shortened during four weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic.” Zaleplon Clinical Study Group. Journal of Clinical Psychiatry. 1999;60(8):536-544.
Erman M. et al, “An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Medicine. Jan 2006;7 (1):17-24.
Erman M., et al, “A crossover study of eszopiclone in the treatment of primary insomnia,” Paper presented at: American Psychiatric Association Meeting Poster Session, 2005.
FDA Statistical review of zaleplon. http://www.fda.gov/cder/foi/nda/99/20859_Sonata_statr.pdf.
FDA. Statistical review of eszopiclone. http://www.fda.gov/cder/foi/nda/2004/021476_Lunesta_statr.PDF.
FDA. Statistical review of ramelteon. http://www.fda.gov/cder/foi/nda/2005/021782s000_Rozerem_statr.pdf.
Fry J., et al, “Zaleplon improves sleep without producing rebound effects in outpatients with insomnia.” Zaleplon Clinical Study Group. Int. Clin. Psychopharmacol. 2000;15(3):141-152.
Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345(dec17 6):e8343-e8343. doi:10.1136/bmj.e8343.
Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med. 2004;164(17):1888–1896.
Krystal A.D. et al, “Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.” Sleep. 2003;26(7):793-799.
Lahmeyer H., et al, “Subjective efficacy of zolpidem in outpatients with chronic insomnia: A double-blind comparison with placebo.” Clinical Drug Investigation. 1997;13(3):134-144.
Lemoine P., et al, “Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months.” European Psychiatry. 1995;10(Suppl 3):161S-165S.
Liu J, Wang L -n. Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis: Ramelteon for chronic insomnia. Int J Clin Pract. 2012;66(9):867-873. doi:10.1111/j.1742-1241.2012.02987.x.
Mendelson, W.B., A review of the evidence for the efficacy and safety of trazodone in insomnia,” J. Clin. Psychiatry (April 2005): 66 (4) 469-476.
National Institutes of Health, “Manifestations and management of chronic insomnia in adults, state-of-the-science consensus statement, (June 13-15, 2005).
Roehrs T. et al, “Efficacy and safety of 6.25 mg of zolpidem modified release formulation in elderly patients with primary insomnia.” Presented at 158th American Psychiatric Association Meeting. Miami, FL, May 21-23, 2005.
Scharf M. et al, “A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.” Sleep. 2005;28(6):714-799.
Schenck C.H., et al, “Assessment and Management of Insomnia.” JAMA 2003;289(19):2475-2479.
Silber, M., “Chronic insomnia,” New Engl. J. Med. (August 25, 2005): 353 (8) 803-810.
Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2008;4(5):487.
Sivertsen, B. et al, “Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults,” JAMA (June 28, 2006): 295 (5), 2851-2858.
Soubrane C. et al, “Efficacy and safety of 12.5 mg of zolpidem modified release formulation in adult patients with primary insomnia,” Presented at 158th American Psychiatric Association Meeting. Miami, FL, May 21-23, 2005.
Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Current Medical Research & Opinion. Jun 2010;26(6):1423-1431.
“Treatment of insomnia,” Treatment Guidelines for the Medical Letter (February 2006): 4 (42).
Tsutsui S. et al, “A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia.” J. Int. Med. Res. 2001;29(3):163-177.
“Your Guide to Healthy Sleep,” National Institutes of Health, U.S. Dept of Health and Human Services, (November 2005) Pub No. 06-5271.
Zammit G.K. et al, “Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.” Curr. Med. Res. Opin. 2004;20(12):1979-1991.